Artificial Intelligence

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

When a 'living drug' for cancer fails, hope fades. A new biologic aims to repaint the target, giving patients' own immune cells a second chance to win.

NJBIZ honors Tevogen for its innovation, but can the biotech firm turn its ambitious multi-billion-dollar forecasts into reality? A deep dive.

A tech-enabled CRO enrolled 550+ oncology patients in six months, a feat that signals a major disruption to the slow, costly drug development process.

A Japanese EdTech firm is offering unlimited free English lessons in Brazil. Is this a savvy market capture or a high-risk gamble in a crowded space?

As consumer debt soars, a key advocacy group's new data-focused leadership could turn a powerful analytical lens on the role of healthcare and drug prices.

WEP's deployment of 700 inspection systems in Missouri showcases its execution, but can it leverage this win in a competitive multi-billion dollar market?

A new Canada-Germany digital alliance promises AI and quantum breakthroughs. But can this pact move from policy to patients and transform Canadian health?

Nokia is doubling down on open networking with SONiC, a strategic move to challenge proprietary giants and carve out a crucial role in AI infrastructure.

Progressive's massive dividend signals immense financial strength, but what does this capital return strategy mean for its innovation and digital future?

A Houston biotech reports a 100% response rate with its new CAR-T therapy, offering a potential lifeline for patients with a devastatingly rare cancer.

A strategic investment in cybersecurity firm ShorePoint reveals how private capital is becoming a critical force multiplier in securing federal agencies.

Nova Era Labs promises to revolutionize AI education with virtual labs. But in a market of giants, can it deliver on its bold claims of workforce readiness?

The U.S. Army awards a major contract for the P550 UAS, a modular, AI-driven drone set to revolutionize battlefield intelligence and soldier safety.

A South Korean biotech's novel antibody, now named rapaprutug, could shift the paradigm for pulmonary arterial hypertension by targeting its root causes.

The biotech is advancing a promising myelofibrosis therapy while developing a next-gen 'super drug,' a dual strategy signaling significant growth.

An Amazon e-commerce firm is making a high-stakes leap into homeland security. Can new leadership and disruptive AI tech transform the company's future?

Sana Biotech’s new data shows it can edit stem cells directly in the body, a potential game-changer for blood disorders and a challenge to current therapies.

As the aging U.S. grid strains under explosive demand, industrial leaders are turning to microgrids for energy independence and financial stability.